JPS6479116A - Remedy for renal disease - Google Patents
Remedy for renal diseaseInfo
- Publication number
- JPS6479116A JPS6479116A JP63143186A JP14318688A JPS6479116A JP S6479116 A JPS6479116 A JP S6479116A JP 63143186 A JP63143186 A JP 63143186A JP 14318688 A JP14318688 A JP 14318688A JP S6479116 A JPS6479116 A JP S6479116A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- remedy
- renal
- diseases
- imidazolylmethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000017169 kidney disease Diseases 0.000 title abstract 5
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 3
- IUTBPRQHFTXNIR-UHFFFAOYSA-N 6-(1h-imidazol-2-ylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid Chemical compound C1CC2=CC(C(=O)O)=CC=C2CC1CC1=NC=CN1 IUTBPRQHFTXNIR-UHFFFAOYSA-N 0.000 abstract 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 2
- 230000003405 preventing effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940126062 Compound A Drugs 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract 1
- 230000002888 effect on disease Effects 0.000 abstract 1
- 239000001530 fumaric acid Substances 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 201000008383 nephritis Diseases 0.000 abstract 1
- 229910017604 nitric acid Inorganic materials 0.000 abstract 1
- 235000002906 tartaric acid Nutrition 0.000 abstract 1
- 239000011975 tartaric acid Substances 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Abstract
PURPOSE:To obtain a remedy for renal diseases having treating and preventing effects on diabetic nephropathy or renal diseases, comprising 6-(1- imidazolylmethyl)-5,6,7,8-tetrahydro-2-naphthalenecarboxylic acid or a salt thereof as an active ingredient. CONSTITUTION:A remedy for renal diseases containing 6-(1-imidazolylmethyl)- 5,6,7,8-tetrahydro-2-naphthalenecarboxylic acid (hereinafter abbreviated as com pound A) or a salt thereof (e.g., hydrochloric acid, sulfuric acid, nitric acid, fumaric acid or tartaric acid) as an active ingredient. Further the remedy has preventing and treating effects on diseases (e.g., diabetic nephropathy, closed nephropathy, ischemic renal failure or nephritis) to cause renal disorder. The compound A has high safety and a dose is usually 30-1,000mg/day per adult daily in oral administration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63143186A JPS6479116A (en) | 1987-06-10 | 1988-06-10 | Remedy for renal disease |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14477987 | 1987-06-10 | ||
| JP63143186A JPS6479116A (en) | 1987-06-10 | 1988-06-10 | Remedy for renal disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS6479116A true JPS6479116A (en) | 1989-03-24 |
Family
ID=26474977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63143186A Pending JPS6479116A (en) | 1987-06-10 | 1988-06-10 | Remedy for renal disease |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6479116A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991015207A1 (en) * | 1990-04-09 | 1991-10-17 | Daiichi Pharmaceutical Co., Ltd. | Remedy for obstructive pulmonary disease |
-
1988
- 1988-06-10 JP JP63143186A patent/JPS6479116A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991015207A1 (en) * | 1990-04-09 | 1991-10-17 | Daiichi Pharmaceutical Co., Ltd. | Remedy for obstructive pulmonary disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE19525598C2 (en) | sleeping pills | |
| MY106259A (en) | 2-aminopyrimidinone derivatives. | |
| GR3031448T3 (en) | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine. | |
| HUP0002373A2 (en) | Glucagon antagonists/inverse agonists | |
| HK1000913A1 (en) | Use of indolone derivatives for the preparation of medicaments for the treatment of parkinsons disease | |
| EG20273A (en) | Process for preparing of pyrazolopyrimidines and their use in the treatment of stress related and other diseases | |
| BG51918A1 (en) | Composition to prevent seasickness (nausea) | |
| US4438138A (en) | Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone | |
| UA19756A1 (en) | Process for preparation of piperazinyle-alkyl-3(2n)pyridazinones or pharmaceutically acceptable salts thereof | |
| IE820539L (en) | Substituted biphenyl compounds | |
| EP0295695A3 (en) | New pyrazoline derivatives and agents for treating cerebnew pyrazoline derivatives and agents for treating cerebrovascular diseases containing the same as active ingredrovascular diseases containing the same as active ingredient ient | |
| CA2166704C (en) | Arsenic medicaments for the treatment of chronic fatigue syndrome | |
| HUT57204A (en) | Process for producing 4-fluoro-2-///4-methoxy-2-pyridinyl/-methyl/-sulfinyl/-1h-benzimidazol with gastric acid secration-diminishing activity and pharmaceutical compositions containing them | |
| JPS6479116A (en) | Remedy for renal disease | |
| EP0319962A3 (en) | Piperidinyl methanol derivatives for the treatment of anxiety | |
| PH24802A (en) | Nasal solutions | |
| JPS6483020A (en) | Medicinal composition for preventing or treating aids | |
| EP0401653A2 (en) | Use of naftopidil for the treatment of dysuria caused by benign prostate hypertrophy | |
| EP0227356A3 (en) | The use of depogen in the treatment of restricted blood circulation | |
| Sander et al. | Nifedipine as an add-on drug in the management of refractory epilepsy | |
| JPS6466125A (en) | Remedy for gastritis | |
| Ruegamer et al. | Growth responses in thyroidectomized, hypophysectomized and alloxan diabetic rats infected with plerocercoids of the tapeworm, Spirometra mansonoides | |
| WO1987003590A1 (en) | Medicament for the treatment of diseases of the liver | |
| AU629520B2 (en) | A medicament | |
| JPS57126422A (en) | Stabilizing method of lysozyme pharmaceutical |